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A sensitive and selective HPLC-peroxyoxalate chemiluminescence (PO-CL) 
method has been developed for the simultaneous determination of chlorpheniramine 
(CPA) and monodesmethyl chlorpheniramine (MDCPA) in human serum.  The method 
combines fluorescent labeling with 4-(4,5-diphenyl-1H-imidazole-2-yl)phenyl boronic 
acid  (DPA) using Suzuki coupling reaction with PO-CL detection.  CPA and MDCPA 
were extracted from human serum by liquid-liquid extraction with n-hexane.  Excess 
labeling reagent which interfered with trace level determination of analytes was 
removed by solid phase extraction using a C18 cartridge.  Separation of derivatives of 
both analytes was achieved isocratically on  silica column with a mixture of acetonitrile 
and 60 mM imidazole-HNO3 buffer (pH 7.2) (=85:15, v/v) containing 0.015% 
triethylamine.  The proposed method exhibited a good linearity with correlation 
coefficient of 0.999 for CPA and MDCPA within the concentration range of 0.5-100 
ng/mL.  The limits of detection (S/N=3) were 0.14 and 0.16 ng/mL for CPA and 
MDCPA, respectively.  Using the proposed method, CPA could be selectively 
determined in human serum after oral administration. 
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CL  Chemiluminescence 
CPA  Chlorpheniramine 
CPPO  Bis(2,4,5-trichlorophenyl-6-carbopenoxyphenyl)oxalate 
DMF  N,N-Dimethylformamide 
DPA  4-(4,5-Diphenyl-1H-imidazole-2-yl)phenyl boronic acid 
FL  Fluorescence 
MDCPA Monodesmethyl chlorpheniramine 
LOD  Limit of detection 
OTC  Over the counter 
PO-CL  Peroxyoxalate chemiluminescence 
RCI  Relative chemiluminescence intensity 
S/N  Signal to noise ratio 








Suzuki coupling reaction is a palladium-catalyzed cross coupling reaction 
between aryl boronic acid and aryl halides or aryl triflates [1].  It has been described as 
the most powerful transformation for the construction of carbon-carbon bonds in 
modern day organic chemistry [2].  Its advantage over other carbon-carbon bond 
forming protocols includes its mild reaction conditions [3,4] and tolerance of a wide 
range of functional groups [4,5].  For analytical application, Suzuki coupling reaction 
provides a route to selectively label a compound containing aryl halide moiety with a 
fluorescent boronic acid derivatives to develop selective analytical methods for aryl 
halide [6].   Its superior selectivity in analysis is derived from minimal interferences 
because most of biological components are not reacted with phenylboronic acid, in 
addition to improved sensitivity brought about by the elimination of a halogen atom, 
which sometimes leads to unexpected quenching of fluorescence (FL) [6].  Lophine 
derivatives have been identified to possess excellent FL properties [7], so we have 
designed a boronic acid derivative of lophine, 4-(4,5-diphenyl-1H-imidazole-2-yl) 
phenyl boronic acid  (DPA) [8].  In one of our previous reports, we demonstrated the 
analytical applicability of Suzuki coupling reaction for the labeling of aryl halides [6].  
We have since employed Suzuki coupling reaction as a pre-column fluorescent labeling 
step to develop sensitive and selective methods for drugs analysis using fluorescence 
detection [9,10].   
 Compared to FL detection methods, chemiluminescence (CL) affords higher 
sensitivity brought about by significant reduction in baseline noise due to the lack of 
external excitation source.  Peroxyoxalate CL (PO-CL) as first reported by Chandross in 
1963 [11] is an indirect CL reaction.  According to the general mechanism, a high 
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energy intermediate is generated by a reaction between aryloxalate ester and H2O2, this 
intermediate transfers its energy to a coexisting fluorophore which becomes excited.  
The excited fluorophore returns to the ground state with the emission of light [12].  
Therefore, fluorescent compounds can be analyzed in an HPLC-PO-CL system by using 
a mixture of aryloxalate ester and H2O2 as a post column reagent, and measuring the 
resulting light signal [13].  Sensitive determinations of non-fluorescent compound have 
been achieved after fluorescent derivatization [14-19].  Therefore, DPA-labeled 
compounds can be detected sensitively using PO-CL reaction. 
 The aim of this study was to use Suzuki coupling reaction  as a fluorescent 
labeling step (Fig. 1)  in combination with PO-CL reaction to develop a sensitive and 
selective method for the determination of chlorpheniramine(CPA) and its metabolite, 
monodesmethyl chlorpheniramine (MDCPA) in human serum.  CPA is a potent, highly 
effective and widely used as an active ingredient in formulations to alleviate symptoms 
of common cold and allergic conditions [20].  CPA is extensively metabolized via N-
dealkylation to its monodemethylated metabolite, MDCPA which accounts for about 
30% of the oral dose [21].   
Various analytical methods have been developed for the determination of CPA, 
some of these are based on HPLC with FL detection [22,23], HPLC with UV detection 
[24 - 28], capillary electrophoresis with UV detection [29], sequential injection analysis 
with electro-chemiluminescence detection [30,31].  However, these methods lack the 
sensitivity for the determination of CPA in biological samples.  Recently, highly 
sensitive methods using HPLC-mass spectrometry (MS) have been developed for the 
determination of CPA [32, 33] or the simultaneous determination of both CPA and 
MDCPA in human plasma [20].  Although these analytical methods employing HPLC-
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MS or HPLC-MS/MS afford high sensitivity, the cost of the equipment still limits its 
application.  Therefore, a highly sensitive and cost-effective method is required. 
  We hereby report the successful combination of fluorescence labeling based on 
Suzuki coupling reaction with PO-CL detection for the first time.  Moreover, we found 
that the sensitivities for CPA and MDCPA obtained by PO-CL detection were 7 and 18 
times higher than those obtained by FL detection.  The proposed PO-CL method should 
become an alternative sensitive and selective method for the simultaneous 






DPA was synthesized as previously reported [6], CPA was purchased from 
Sigma Chemical (St Louis, USA), MDCPA was kindly donated by Schering-Plough, 
Japan.  N,N-Dimethylformamide (DMF), N, N-diethylacetamide (DEA), palladium 
acetate (Pd(OAc)2), cesium carbonate (Cs2CO3), tetrahydrofuran (THF), 10%  nitric 
acid (HNO3), acetonitrile and  n-hexane, were purchased from Nacalai Tesque (Kyoto, 
Japan).  Imidazole, bis(2,4,6-trichlorophenyl)oxalate (TCPO) was bought from Tokyo 
Chemical Industry (Tokyo, Japan).  Tripotassium phosphate (K3PO4), trisodium 
phosphate (Na3PO4), potassium tert-butoxide (t-BuOK), triethylamine (TEA) and bis[2-
(3,6,9-trioxadecanyloxycarbonyl)-4-nitrophenyl]oxalate (TDPO) were obtained from 
Wako Pure Chemical (Osaka, Japan).  Bis(2,4,5-trichlorophenyl-6-
carbopenoxyphenyl)oxalate (CPPO) was a kind gift from Lumica (Fukuoka, Japan).  
All other reagents used were of analytical grade. 
 
2.2. Instrument 
The HPLC-PO-CL system consisted of two Shimadzu LC-10AT pumps, 
(Shimadzu, Kyoto, Japan) and a Rheodyne 7125 injector with a 20-L loop (Cotati, CA, 
USA). Chromatographic separation was achieved isocratically on a Lichrosorb Si100 
column (5 m, 250 × 4.0 mm i.d.) (GL Science, Tokyo, Japan) using a mixture of 
acetonitrile-60 mM imidazole-HNO3 buffer (pH 7.2) (=85:15, v/v) containing 0.015% 
TEA as the mobile phase.  CL signal was measured with a Shimadzu CLD-10 CL 
detector using a mixture of 0.8 mM CPPO and 30 mM H2O2 in acetonitrile as the post 
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column reagent. The mobile phase and the post column reagent were degassed 
thoroughly before use.  For the fluorescence detection of DPA-labeled CPA and 
MDCPA, Shimadzu RF-550 detector was employed and excitation and emission 
wavelengths were set at 320 and 410 nm, respectively. 
 
2.3. Assay procedure for CPA and MDCPA 
To a 200-L portion of the serum, 100 L of 0.4 M NaOH was added and 
vortexed briefly, after which 3 mL of n-hexane was added.  The mixture was vortexed 
for 5 min and centrifuged at 3000×g at 4 °C for 5 min.  The organic layer was carefully 
taken and evaporated to dryness using centrifugal evaporator.  The residue was 
reconstituted in 50 L of DMF and subjected to the fluorescence labeling as follows: 
50-L portion each of 10 mM DPA in DMF, 4 mM Pd(OAc)2 in DMF and 50 mM 
Cs2CO3 in water were added to the reconstituted residue.  The mixture was vortexed for 
10 s and deoxygenated by N2 purge for 20 s.  The reaction mixture was heated at 100 °C 
for 40 min.  After the reaction, the reaction mixture was diluted to 1 mL with a mixture 
of water and methanol (20:80, v/v) containing 0.1 % TEA and applied to a solid-phase 
cartridge to remove excess DPA.  The SPE cartridge (Inertsil Slim C18 B, GL Science) 
was preliminary washed with 4 mL of methanol and 4 mL of water.  The diluted 
reaction mixture was then applied and washed twice with 1 mL of acetonitrile 
containing 0.1% TEA, the labeled analytes were eluted with THF containing 0.01% 
trifluoroacetic acid.  The eluate was evaporated to dryness, re-constituted in 100 L 
DMF and passed through a membrane filter (0.5 mDISMIC-3, Toyo Roshi, Japan).  




2.4. Sample collection 
This section of experiments was approved by the Ethics Committee of the 
Graduate School of Biomedical Sciences, Nagasaki University (approval number 24) 
and performed under established guidelines. The healthy volunteer was orally 
administered over-the-counter (OTC) preparation containing 6 mg of CPA 2 h before 
sampling.  The blood sample was kept on ice and allowed to clot.  It was centrifuged at 
1000×g at 5 °C for 10 min to obtain serum.  The samples were kept at -80 °C  in 




3. Results and discussion 
3.1. Optimization of labeling conditions 
In this study, the conditions for the labeling reaction were optimized using 
standard solution of CPA and MDCPA.  The yield of the labeling reaction was 
monitored using the relative FL intensity (RFI).  Dioxane, DEA, DMF and isopropanol 
were investigated as the solvent for the reaction.  The highest RFI was observed with 
DMF which was selected as the solvent for the labeling reaction.  The concentration of 
DPA was optimized over the range of 6-12 mM.  The highest RFI was obtained at 10 
mM.  Na2CO3, Cs2CO3, K3PO4, Na3PO4 and t-BuOK were also investigated as the base 
for the labeling reaction.  The highest RFI for CPA and MDCPA was obtained for 
Cs2CO3.  Although we have developed the determination methods for some aryl 
chloride drugs by Suzuki coupling reaction with DPA [6,9,10], Cs2CO3 was used for the 
first time as a base catalyst for Suzuki coupling reaction in this study.  The application 
of Cs2CO3 to DPA labeling reaction may improve the sensitivities of the method for 
such aryl chloride drugs because Cs2CO3 gave higher reactivity.  Subsequently, the 
concentration of Cs2CO3 was studied over the range of 10-60 mM.  The maximum and 
constant peak heights were obtained with more than 40 mM Cs2CO3 (Fig. 2); 50 mM 
was selected as optimum concentration.  Pd(OAc)2 was decisively selected as the 
catalyst due to its success for the labeling reaction in our previous reports [6,9,10].  The 
concentration of Pd(OAc)2 was varied from 1 to 5 mM, the optimum RFI was observed 
over 3 mM; 4 mM was selected.  The temperature and the time for the reaction were 
also investigated.  Increase in RFI was observed as temperature increases.  At 100 °C, 
the optimum time for the reaction was 40 min. 
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After the derivatization step, excess DPA interfered with trace level 
determination of both analytes.  To remove the excess DPA, a sample cleaning step 
with SPE procedure was incorporated into the experimental procedure as already 
described in the experimental section.  Percentage recoveries (mean±SD, n=3) of CPA 
and MDCPA were 86.0±3.0% and 87.5±3.0%, respectively.  
 
3.2. Optimization of PO-CL conditions 
The CL conditions for the determination of CPA and MDCPA were optimized 
using the HPLC-PO-CL system described in the experimental section.  Optimum 
conditions were selected by monitoring the relative CL intensity (RCI) and signal-to-
noise ratio (S/N) for the peaks of CPA and MDCPA.  Imidazole has been identified as 
the best catalyst for the PO-CL reaction; it has been established that imidazole catalyses 
the slow 1, 2-dioxethanedione generation reaction between the aryloxalate and H2O2.  
Imidazole acts not only through basic catalysis but also nucleophilic catalysis pathway 
[34, 35].  Imidazole solution was used as the aqueous portion of the mobile phase.  The 
concentration of imidazole was optimized over the range of 0-100 mM. The highest 
RCI and S/N was observed at 40 and 60 mM; the optimum concentration was 60 mM.  
The acid used in combination with imidazole has also been found to significantly 
influence the CL signal.  Several acids were tried including HClO4, CF3COOH, HNO3 
and CH3COOH.  Maximum RCI and S/N ratio were observed with the use of 
imidazole-HNO3 combination (Fig. 3).  This result is consistent with previously reports 
[17,36,37].  The pH of the mobile phase was also optimized over the range of 6.8-7.6. 
This range was selected because lower pH values lead to loss of retention of the 
analytes.  There is also risk of dissolution of the silica gel with the use of aqueous 
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mobile phase with pH above 8, and the consequent distortion of column efficiency [38].  
The addition of TEA in the mobile phase is very necessary since it acts as masking 
agent on the silica gel to minimize interaction between basic analytes and the silica gel, 
which generally causes tailing of peaks and results in longer retention times [39].  For 
these reasons, 0.015% was added to the mobile phase prior to the adjustment of the pH 
with HNO3.  The optimum pH of the mobile phase was 7.2.  The type of aryloxalate 
was also optimized.  Aryloxalates with electron withdrawing groups are known to 
provide highest quantum yield [40].  The effects of CPPO, TDPO and TCPO on RCI 
and S/N were investigated.  CPPO gave the best RCI and S/N ratio for both CPA and 
MDCPA.  The concentration of CPPO was varied from 0.1 to 1.0 mM.  The optimum 
concentration of CPPO was 0.8 mM (Fig. 4).  The concentration of H2O2 was also 
optimized from 0.1 to 40 mM. The best RCI and S/N were at 30 mM.  Finally, the flow 
rate of the CL reagent was varied from 0.2 to 1.4 mL min-1, increase in signal intensity 
commensurate flow rate, however, flow rate above 1.3 mL min-1 led to an increase in 
background noise.  The flow rate of the CL reagent was set at 1.2 mL min-1, since the 
best RCI and S/N ratio were best at this point.  A chromatogram of standard solution of 
CPA and MDCPA after optimization of FL labeling conditions and PO-CL conditions is 
shown in Fig. 5. 
 
3.3. Method validation 
Under the optimized conditions, linear relationship was observed by plotting a 
concentration of analytes (ng/mL) against CL intensity using spiked human serum 
samples.  The calibration range, correlation coefficient and limits of detection (LOD) 
for the calibration curve (n=3) are shown in Table 1.  
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A good linearity was observed with a correlation coefficient of 0.999 for both 
analytes in the concentration range of 0.5-100 ng/mL with 8 calibration points.  The 
LODs (S/N=3) for CPA and MDCPA were 0.14 and 0.16 ng/mL, respectively.  On the 
other hand, the LODs (S/N=3) for CPA and MDCPA obtained by FL detection were 2.5 
and 1.1 ng/mL, respectively.  This results indicated that the application of PO-CL for 
the detection of  DPA labeled compound could improve the sensitivity.  Fig. 6 (A) and 
(B) shows representative chromatograms of blank human serum and human serum 
spiked with a standard solution of CPA and MDCPA.  Since DPA could react 
specifically with aryl halides and did not react with most of serum components, both 
analytes can be detected clearly without interference on the chromatogram.  
Accuracy and precision of the proposed method were accessed at three different 
concentration levels: low (2 ng/mL), intermediate (20 ng/mL) and high (80 ng/mL) 
concentration on three different days for both analytes.  The results of these experiments 
are illustrated in Table 2.  The intra- and inter-day accuracy of CPA ranged from 89.3% 
to 103.5% with precision values less than 10.8%.  MDCPA had intra- and inter-day 
accuracy ranging between 92.2% and 103.5% with precision values less than 10.2%.  
These results indicate that the proposed method showed good accuracy and precision.  
The proposed method has sensitivity >300 fold that of HPLC-UV [25,28,27] and >15 
fold that of other CL methods [30,31] for the determination of CPA.  Also, the detection 
limit of the proposed method was almost same as that of HPLC-MS methods [20,32,33].  
However, the sample amount subjected to analysis of the proposed method (200 µL) 
was smaller than that of the HPLC-MS methods (0.5 or 1.0 mL).  In addition, the 
proposed HPLC system can be constructed inexpensively compared with those of 
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HPLC-MS methods.  Therefore, proposed HPLC-CL method should become a cost-
effective alternative for the analysis of CPA and MDCPA. 
 
3.4. Determination of CPA and MDCPA in human serum  
The proposed method was applied to the determination of CPA and MDCPA in 
human serum samples after oral administration of CPA.  The blood sample was 
collected from a subject who used OTC preparations that contain CPA.   Fig. 7 shows 
the chromatogram of serum sample of the subjects after a single oral administration of 6 
mg of CPA. The concentration of CPA in this chromatogram corresponds to 3.5 ng/mL, 
and the value was similar to previous studies [20, 32-33].   On the other hand, MDCPA 
was not detected on the chromatogram in the present study.  This might be due to the 
presence of concentrations that are lower than the LOD.  To determine MDCPA, 





Suzuki coupling reaction as a fluorescent labeling step has been successfully 
applied to PO-CL detection to develop a sensitive and selective method for the 
simultaneous determination CPA and MDCPA in human serum.  The derivatization 
principle employed reduces interference since naturally occurring aryl halides in 
biological samples are limited. The sensitivity of the proposed method is many folds 
better than HPLC-UV and CL methods, and is comparable to HPLC-MS methods with 
smaller sample amounts.  This method has been shown to be able to determine CPA in 
human serum after oral administration.  
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Fig. 2  Effect of Cs2CO3 concentration on RFI of CPA and MDCPA.  
Labeling conditions: concentrations of analyte, DPA and Pd(OAc)2 were 5g/mL, 10 









Fig. 3  Effect of acid modifier on (A) RCI and (B) S/N of CPA and MDCPA. 
Labeling conditions: same as Fig. 2.  Eluent (flow rate, 1.0 mL/min): acetonitrile-60 
mM imidazole solution (85:15, v/v) containing 0.015% TEA, (pH 7.4).  CL reagent 








Fig. 4  Effect of CPPO concentration on (A) RCI and (B) S/N of CPA and MDCPA. 
Labeling conditions and eluent: same as Fig. 3 CL reagent: CPPO and 30 mM H2O2 in 











Fig. 5  Chromatograms of (A) reagent blank, (B) standard solution of CPA and 
MDCPA (0.5 g/mL) with PO-CL detection, and (C) standard solution of CPA and 
MDCPA (0.5 g/mL) with FL detection.   












Fig. 6  Chromatograms of (A) blank human serum and (B) human serum spiked with 
















Fig. 7  Chromatogram of extract from human serum 2 h after oral administration of 6 
mg CPA. (Detector response is 4 times higher than that of Fig. 6.    
Conditions: as mentioned in experimental section. 
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Table 1  Calibration curves and detection limits of CPA and MDCPA in human serum 
Sample Range, ng mL
-1
Equation (n=3)* Linearity
CPA 0.5-100 y  =1.52±0.02 x- 0.87±1.05 0.999
MDCPA 0.5-100 y  =1.42±0.03x-0.72±1.97 0.999
*y = peak height (cm); x = sample concentration (ng mL-1); mean ± SD
**S/N=3
         0.14, 5.2










Table 2  Intra- and inter-day accuracy and precision of the proposed method for 








2 100.9 ± 5.1 6.1 89.3 ± 7.6 10.8
20 100.4 ± 5.0 5.1 94.5 ± 2.6 7.9
80 98.9 ± 3.3 3.4 103.5 ± 2.2 2.1
MDCPA
2 96.7 ± 8.1 10.2 93.6 ± 7.2 9.4
20 100.0 ± 2.0 2.1 103.5 ± 5.4 5.3
80 98.2 ± 4.3 4.3 92.2 ± 6.1 6.7
a
Mean ± SE
   Intra-day (n=3)    Inter-day (n=3) 
 
 
